Bacterial Superantigen Toxins, CD28, and Drug Development

Area of Science:

• Immunology
• Microbiology
• Pharmacology

Background:

• Severe bacterial infections can cause life-threatening conditions due to excessive host immune responses.
• Superantigen toxins from Gram-positive bacteria induce toxic shock by massively overstimulating inflammation.
• The principal costimulatory receptor CD28 and its coligand B7-2 (CD86) were investigated for their role in superantigen-induced responses.

Purpose of the Study:

• To identify novel receptors involved in superantigen toxin activity.
• To understand the mechanism by which superantigens engage host immune receptors.
• To develop novel therapeutic strategies targeting superantigen-mediated immune hyperactivation.

Main Methods:

• Investigated the interaction between superantigen toxins and host immune receptors, including CD28 and B7-2.
• Analyzed the role of receptor-ligand interfaces in mediating inflammatory signaling.
• Designed and tested peptide mimetics targeting these receptor interfaces.

Main Results:

• Identified CD28 and B7-2 as critical receptors for superantigen toxins, not just costimulatory molecules.
• Demonstrated that superantigens bind to homodimer interfaces of CD28/B7-2, enhancing their engagement and pro-inflammatory signaling.
• Developed receptor dimer interface mimetic peptides that block superantigen binding and protect against lethal bacterial infections, including Gram-negative and polymicrobial sepsis.

Conclusions:

• CD28 and B7-2 are key receptors for superantigens, mediating excessive inflammation.
• Peptide inhibitors targeting the CD28/B7-2 interface offer a novel therapeutic approach for severe bacterial infections.
• Host-targeted therapies, like CD28 mimetic peptides, show promise in clinical trials and reduce pathogen resistance.
• These findings have implications for treating toxic shock and other life-threatening infections.